1,3-Dihydro-2H-1,5-benzodiazepin-2-one | 65749-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 1,3-Dihydro-2H-1,5-benzodiazepin-2-one
• 英文别名: 1,3-dihydro-1,5-benzodiazepin-2-one
• CAS: 65749-98-6
• 化学式: C₉H₈N₂O
• 分子量: 160.17
• InChiKey: LDCMTXMRTVOLKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  、 [(2-Aminophenyl)amino]methyl 3-oxopropanoate 、 邻二甲苯 以to give 1,3-dihydro-2H-1,5-benzodiazepin-2-one, which的产率得到1,3-Dihydro-2H-1,5-benzodiazepin-2-one
  参考文献：
  名称：

  GPR17 Receptor Modulators

  摘要：

  提供了一些化合物，这些化合物作用于GPR17受体，并且在治疗或改善慢性和/或急性神经退行性疾病方面非常有用，例如多发性硬化症、炎症性疾病、涉及免疫系统的病理学、心血管疾病和肾脏疾病。

  公开号：

  US20150141410A1

文献信息

• Dihydro-benzo[b][1,4]diazepin-2-one derivatives
  申请人：——

  公开号：US20030166639A1

  公开（公告）日：2003-09-04

  This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula 1 wherein R 1 , R 2 , X and Y are as defined in the specification and R 3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.

  这项发明涉及公式为1的二氢苯并[b][1,4]二氮杂二氢吡嗪-2-酮衍生物，其中R 1 ，R 2 ，X和Y如规范中所定义，R 3 是含有1至3个氮原子的六元芳香杂环或如规范中进一步定义的吡啶-N-氧化物。该发明还涉及含有这些化合物的药物、它们的制备方法以及它们用于制备治疗或预防急性和/或慢性神经系统疾病的药物。
• [EN] HUMAN PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE HUMAINE
  申请人：BIOCRYST PHARM INC

  公开号：WO2015134998A1

  公开（公告）日：2015-09-11

  Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

  本文披露的是公式（I）的化合物及其药用盐。这些化合物是血浆激肽酶的抑制剂。还提供了包含本发明化合物的药物组合物，以及涉及使用这些化合物和组合物治疗和预防由不需要的血浆激肽酶活性特征的疾病和症状的方法。
• [EN] COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS<br/>[FR] COMBINAISON D'ANTAGONISTE MGLUR2 ET D'INHIBITEUR ACHE DESTINEE AU TRAITEMENT DE TROUBLES NEUROLOGIQUES AIGUS ET/OU CHRONIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005014002A1

  公开（公告）日：2005-02-17

  The present invention relates to a method of treatment or prevention of acute and/or chronic neurological disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and. to kits comprising an AChE inhibitor and a mGluR2 antagonist.

  本发明涉及一种治疗或预防急性和/或慢性神经系统疾病的方法，涉及一种包含乙酰胆碱酯酶抑制剂（AChE抑制剂）和代谢型谷氨酸受体2拮抗剂（mGluR2拮抗剂）的药物组合物，涉及在制备药物中使用AChE抑制剂和mGluR2拮抗剂，以及包含AChE抑制剂和mGluR2拮抗剂的试剂盒。
• Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides
  申请人：EASTMAN KODAK COMPANY

  公开号：EP0487155A1

  公开（公告）日：1992-05-27

  A method of controlling fungi comprising contacting the fungi with a fungicidally effective amount of a benzodiazepine of the structure: wherein    R¹ is substituted or unsubstituted, straight or branched alkyl having from 3 to 10 carbon atoms, or substituted or unsubstituted aryl having from 6 to 20 carbon atoms,    R² is substituted or unsubstituted, straight or branched alkyl having from 1 to 10 carbon atoms, or substituted or unsubstituted aryl having from 6 to 20 carbon atoms,    R³ is hydrogen, halogen, substituted or unsubstituted alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms, or substituted or unsubstituted aryl having from 6 to 20 carbon atoms, and    R⁴ is hydrogen or halogen, provided that when R4 is halogen, R³ is the same halogen.

  一种控制真菌的方法，包括将真菌与具有以下结构的苯二氮䓬类药物的有效量接触：其中R¹是取代或未取代的、直链或支链的碳原子数为3到10的烷基，或取代或未取代的碳原子数为6到20的芳基，R²是取代或未取代的、直链或支链的碳原子数为1到10的烷基，或取代或未取代的碳原子数为6到20的芳基，R³是氢、卤素、取代或未取代的碳原子数为1到10的烷基、碳原子数为2到10的烯基，或取代或未取代的碳原子数为6到20的芳基，R⁴是氢或卤素，但当R⁴为卤素时，R³为相同的卤素。
• Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
  申请人：——

  公开号：US20020193367A1

  公开（公告）日：2002-12-19

  This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula 1 wherein R 1 , R 2 , R 3 , X and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation, their use in preparation of pharmaceutical compositions and administration of an effective amount of the compounds for the treatment or prevention of acute and/or chronic neurological disorders to a patient in need of such treatment.

  这项发明涉及一种公式1中R1、R2、R3、X和Y如规范中所定义的二氢苯并[b][1,4]二氮杂环-2-酮衍生物。该发明包括含有这些化合物的药物组合物、制备它们的方法、它们在制备药物组合物时的使用以及给需要这种治疗的患者施用足够剂量的这些化合物以治疗或预防急性和/或慢性神经系统疾病。